$ATNF ... Reason to Buy Today ..
currently $6.75 (2 Day PT: $11... 1-2Mo PT: $20
Cup Pattern: ppl are slowly becoming aware of the company and incredible team & pipeline... and the Price has risen to $6.75 (from initial Drop... see below). It now appears likely to complete the run up back to $11 to complete a Cup pattern by End of week (due to no resistance over $7 bc of initial drop). And due to the Cup Depth of $9 ... the rebound from the subsequent handle has a Price Target of $20 (next 1-2 months).
At $20 the Market Cap would only be around $400M .. which is likely an accurate current valuation. (Approval of the $7B Phase 3 Drug by EOY would take the share price at very least above $80). So today is the best timing to get in below $7... and likely take advantage of both the run up to $11 then $20. And be able to hold for bigger potential returns longer term.
Background/ DD:
180 Life Sciences (ATNF) is a $125M biotech. Vanguard acquired over 11% stake last week for 2 of its funds. $7B Anti-TNF Drug will get Phase 3 results later in the year (Highly likely approval). Strong Pipeline. The management Team will literally blow you away....they own over 55% of shares which are locked for 12 months & they are talking no salaries. Also, Anti-TNF Platform trials are fully grant-funded through completion % no offerings for at least 3 years. Stock is about to form a Cup pattern (Cup/Handle).
Management: ATNF management team is as good as any Large Cap: 2 of the co-founders discovered Anti-TNF Biologics & successfully completed trials phases & approval for the 1st approved Drug in the class- Remicade, which JNJ bought for over $5B. (This class is now the top-selling class of Drugs in the world... ie Remicade, Humira, Enbrel- these 3 alone sold $35B in the US in 2020). Marc Feldmann won a Lasker award (only 2nd to Nobel) for the discovery. Anti-TNF is 1 of their 3 platforms. Another Co-Founder discovered the body's endocannabinoid system & will likely be a 2021 Nobel nominee for formulating synthetic CBD analogs (which is the 2nd of ATNF's platforms). Additionally, the team collectively have sold Drugs or Companies to JNJ, Amgen, Biogen, and Bristol Myers.. each transaction was over $4B. Team also includes Prior President of Roche Bio, Chair of Clinical research prof at Standford & another with the same title at Oxford. (You can find full bios on 180LifeSciences.com).
Initial drop: (why so undervalued currently) The company formed via the merger of 3 small biotech through a SPAC that went public 3 months ago. Due to a long clucky SPAC process, with horrible marketing (everyone thought this was a "european pot stock" bc the company being acquired was listed as CannaRX Bio- b/c that happen to be the 1 used for paperwork name. Combined this with an offering that included Rights & Warrants, and the multiple extensions- the price of Right & Warrant remained very low & on merge day, when Right converted- the Share Price dropped below $3. This had nothing to do with the fundamental of the company- but rather an awful SPAC process (the SPAC manager is no longer associated with the company and sold most of her shares past several months (prob to avoid a lawsuit).
AI
